Allarity Therapeutics, Inc. · NASDAQ:ALLR
Allarity Therapeutics — Oncology Venture — Shareholder Meeting (March 2020)
8 slides from Allarity Therapeutics's shareholder meeting presentation, Mar 31, 2020
Slide 1: Annual Report 2019 Investor Presentation
Annul Report 2019 Investor Presentation 31 March, 2020
Slide 2: Agenda
Agenda - COVID-19 (Steve Carchedi) - General Business Update (Steve Carchedi) - 2019 Financial Highlights (Henrik Moltke) - Q&A
Slide 3: Disclaimer
This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation,
Slide 4: COVID-19
- We comply with national guidelines - Most employees work from home - No delay in our internal operations COVID-19 Key takeaways - Delay may occur at clinical trial sites
Slide 5: Strategic Realignment and Execution
- New Executive Management team - New Strategy Dovitinib Strategic ◦ Commercialization ◦ Dovitinib Realignment ◦ 2X-121 - 121 and Execution ◦ IXEMPRA® Key takeaways - Dovitinib ◦ Guidance received from the FDA ◦ Focus on non-inferiority to Sorafenib/Nexavar® ◦ Accompanying DRP® application will be f
Slide 6: 2019 Financial Highlights
- 100 million SEK share issue - Introduced robust financial controls - Across-the-board cost reductions 2019 Financial - Year ended with balance sheet without debt Highlights Key takeaways - Today’s new financing deal: Convertible loan of up to 100 million SEK, solely to be decided by OV
Slide 7: New Financing
- Up to 100 mill. In 10 tranches in 24 months - Flexible – from 0 – 100 mill SEK - Conversion price at 95 % - Coupon rate: 0 % New Financing - No warrants Key Takeaways - No ‘share lending’ - We are in full control
Slide 8: Q&A Session
~ Q&A Session